Company news

Viatris Inc. news in 2024

Viatris Inc.'s news releases, calls and decks from 2024, newest first.

View company

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

December 17, 2024

Viatris Reports Third Quarter Financial Results for 2024

November 6, 2024

Viatris Announces Third Quarter 2024 Dividend

November 4, 2024

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

October 28, 2024

Viatris Named to Forbes' World's Top Companies for Women 2024 List

October 28, 2024

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

October 15, 2024

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

October 8, 2024

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row

October 7, 2024

Viatris Announces the Pricing Terms of Maximum Tender Offer

September 17, 2024

Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer

September 16, 2024

Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024

September 15, 2024

Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers

September 9, 2024

Viatris Announces Expiration and Results of Any and All Cash Tender Offers

September 9, 2024

Viatris Announces Cash Tender Offers for Certain Outstanding Notes

September 3, 2024

Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

August 22, 2024

Viatris Reports Second Quarter Financial Results for 2024

August 7, 2024

Viatris Announces Second Quarter 2024 Dividend

August 5, 2024

Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture

July 2, 2024

U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation

July 1, 2024

Viatris Named to TIME's World's Most Sustainable Companies 2024 List

June 24, 2024

Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024

June 6, 2024

Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 3, 2024

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

June 2, 2024

Viatris to Participate in the Jeffries Global Healthcare Conference

May 30, 2024

Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale

May 20, 2024

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges

May 8, 2024

Viatris to Participate in the BofA Securities 2024 Health Care Conference

May 1, 2024

Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health

April 30, 2024

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024

April 15, 2024

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

April 14, 2024

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

March 31, 2024

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

March 26, 2024

Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

February 27, 2024

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

February 27, 2024

Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results

February 4, 2024

Calls in 2024

Decks in 2024